Search

Proton therapy offers a way to treat pediatric cancers more safely.

… Tuesday, June 18, 2019 Summary Children are especially sensitive to the side effects of conventional radiation therapy. For some pediatric cancers, proton therapy can be used to destroy tumors while minimizing risks. Radiation therapy is quite effective at shrinking or eliminating tumors. But doctors

Learn how MSK helped a man with stage 4 stomach (gastric) cancer using checkpoint inhibitors, a type of immunotherapy that also treats many other cancers.

… Thursday, July 3, 2025 Antonio Lekhrajmal knew his diagnosis of advanced  stomach cancer — also called gastric cancer — was extremely serious. He credits his doctor, Memorial Sloan Kettering Cancer Center (MSK) gastrointestinal oncologist Yelena Janjigian, MD , with being upfront with him, and treating

Physicians and scientists from MSK presented advances in transplantation and cellular therapies at the Tandem Meetings, a joint event hosted by the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.

… Tuesday, February 25, 2025 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) presented advances in transplantation and cellular therapies at the Tandem Meetings, a joint event hosted by the American Society for Transplantation and Cellular Therapy and the Center for International

Chris Lee’s story begins in the 1940s, when his maternal grandfather boarded a ship in China headed to America.

… Friday, May 27, 2022 Chris Lee’s story begins in the 1940s, when his maternal grandfather boarded a ship in China headed to America. Like tens of millions of immigrants, Mr. Wong entered the U.S. via Ellis Island Immigration Station, with the “hopes of making a better life for his family and their future

A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.

… Friday, February 29, 2008 A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.

… Saturday, December 6, 2014 In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance

Learn what detection of the polio virus in New York State means for you.

… Monday, September 12, 2022 Polio has been in the news after the poliovirus was detected in wastewater samples of several New York counties — including New York City — and a person was identified as having the disease by New York health officials in July. On September 9, Gov. Kathy Hochul declared a state

A new study from Memorial Sloan Kettering Cancer Center has found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival.

… Sunday, October 24, 2021 A new study from Memorial Sloan Kettering Cancer Center found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival. This is the first and largest randomized clinical

Epcoritamab plus R2 resulted in substantial increases in the objective response rate and progression-free survival compared to R2 alone, the co-primary endpoints of the trial. The triplet combination also outperformed the standard-of-care on the secondary endpoints of complete response rate and duration of response. Lorenzo Falchi, MD, presented the latest results for the study at the American Society of Hematology's 67th Annual Meeting and Exposition in Florida.

… Sunday, December 7, 2025 On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved the triplet epcoritamab plus lenalidomide and rituximab (R 2 ) for patients with relapsed or refractory follicular lymphoma, based on groundbreaking results from the phase 3 EPCORE FL-1 Trial ( NCT05409066

Learn about a possible new treatment approach for soft tissue sarcomas.

… Monday, February 5, 2024 Epithelioid sarcoma , a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors , which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue sarcoma brightened in 2020 when the Food and Drug Administration